NAMPT Inhibitor GMX1778 Enhances the Efficacy of 177Lu-DOTATATE Treatment of Neuroendocrine Tumors

Neuroendocrine tumors (NETs) can be treated by peptide receptor radionuclide therapy using radiolabeled somatostatin analogs. However, the efficacy of such treatment is low and needs to be optimized. Our study evaluated the potential radiosensitizing effects of inhibition of nicotineamide phosphoribosyltransferase on 177Lu-DOTATATE treatment in a NET model. Methods: Nude mice xenografted with the human NET cell line GOT1 were treated with semiefficient doses of 177Lu-DOTATATE (7.5 MBq, intravenously) or the nicotineamide phosphoribosyltransferase inhibitor GMX1778 (100 mg/kg/wk, orally). Results: Median time to tumor progression (tumor volume larger than at day 0) was 3 d for controls, 7 d for single-dose GMX1778, 28 d for single-dose 177Lu-DOTATATE, 35 d for 3 weekly doses of GMX1778, and 98 d for combined treatment with 177Lu-DOTATATE and GMX1778 × 1. After 177Lu-DOTATATE and 3 weekly doses of GMX1778, none of the tumors progressed within 120 d. Conclusion: GMX1778 enhances the efficacy of 177Lu-DOTATATE treatment and induces a prolonged antitumor response.

[1]  J. Turner,et al.  Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors. , 2012, Cancer biotherapy & radiopharmaceuticals.

[2]  Eva Forssell-Aronsson,et al.  Successful receptor-mediated radiation therapy of xenografted human midgut carcinoid tumour , 2005, British Journal of Cancer.

[3]  Chris Twelves,et al.  Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study. , 2005, European journal of cancer.

[4]  R. Hicks,et al.  High-administered activity In-111 octreotide therapy with concomitant radiosensitizing 5FU chemotherapy for treatment of neuroendocrine tumors: preliminary experience. , 2009, Cancer biotherapy & radiopharmaceuticals.

[5]  M. Ziegler,et al.  The NAD metabolome — a key determinant of cancer cell biology , 2012, Nature Reviews Cancer.

[6]  C. Sundberg,et al.  Metronomic administration of the drug GMX1777, a cellular NAD synthesis inhibitor, results in neuroblastoma regression and vessel maturation without inducing drug resistance , 2010, International journal of cancer.

[7]  Karine Gilbert,et al.  The Small Molecule GMX1778 Is a Potent Inhibitor of NAD+ Biosynthesis: Strategy for Enhanced Therapy in Nicotinic Acid Phosphoribosyltransferase 1-Deficient Tumors , 2009, Molecular and Cellular Biology.

[8]  T. Akhurst,et al.  Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedside , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  Eva Forssell-Aronsson,et al.  Animal Model A Transplantable Human Carcinoid as Model for Somatostatin Receptor-Mediated and Amine Transporter-Mediated Radionuclide Uptake , 2001 .

[10]  J. Koutcher,et al.  Metabolic Signatures Associated with a NAD Synthesis Inhibitor–Induced Tumor Apoptosis Identified by 1H-Decoupled-31P Magnetic Resonance Spectroscopy , 2005, Clinical Cancer Research.

[11]  Rolf Larsson,et al.  A Phase I study of CHS 828 in patients with solid tumor malignancy. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  V. Schreiber,et al.  Poly(ADP-ribose): novel functions for an old molecule , 2006, Nature Reviews Molecular Cell Biology.

[13]  R. Bristow,et al.  Efficacy of Combining GMX1777 with Radiation Therapy for Human Head and Neck Carcinoma , 2010, Clinical Cancer Research.

[14]  Marion de Jong,et al.  Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. , 2010, Endocrine-related cancer.

[15]  T. Akhurst,et al.  Favourable outcomes of 177Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  O. Nilsson,et al.  Antitumoural Effects of the Pyridyl Cyanoguanidine CHS 828 on Three Different Types of Neuroendocrine Tumours Xenografted to Nude Mice , 2006, Neuroendocrinology.

[17]  A. Roulston,et al.  Synergy between the NAMPT inhibitor GMX1777(8) and pemetrexed in non-small cell lung cancer cells is mediated by PARP activation and enhanced NAD consumption. , 2014, Cancer research.

[18]  J. Reubi,et al.  Somatostatin Receptor Subtype 2A Immunohistochemistry Using a New Monoclonal Antibody Selects Tumors Suitable for In Vivo Somatostatin Receptor Targeting , 2012, The American journal of surgical pathology.

[19]  M. de Jong,et al.  Update: improvement strategies for peptide receptor scintigraphy and radionuclide therapy. , 2008, Cancer biotherapy & radiopharmaceuticals.

[20]  R. Larsson,et al.  CHS 828 Inhibits Neuroblastoma Growth in Mice Alone and in Combination with Antiangiogenic Drugs , 2002, Pediatric Research.

[21]  E. Krenning,et al.  Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours , 2008, European Journal of Nuclear Medicine and Molecular Imaging.